Sitagliptin Approved As Add-on To InsulinMain Category: DiabetesAlso Included In: Regulatory Affairs / Drug Approvals Article Date: 22 Nov 2009 Sitagliptin (known as Januvia) has been approved by the European Commission as an add-on to insulin (with or without metformin) for people with Type 2 diabetes who cannot control their condition effectively with a combination of diet, physical activity and insulin. Sitagliptin is a once-daily DPP-4 inhibitor that works by blocking the action of DPP-4, an enzyme which destroys the hormone incretin. Incretins help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. Further option for people with Type 2 diabetes "We welcome this announcement that sitagliptin will be made available, as it can offer people with Type 2 diabetes a further option to help them achieve good glycaemic control," said Caroline Butler, Care Advisor at Diabetes UK. Source Diabetes UK Original article posted on Medical News Today. Articles not to be reproduced without permission of Medical News Today Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles. < back to medical news
|
||||
|





